AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

STARPHARMA HOLDINGS LTD

0.415

+0.0153.75%

Volume:5.82M

Turnover:2.33M

Market Cap:173.56M

PE:-17.33

High:0.415

Open:0.400

Low:0.400

Close:0.400

52wk High:0.445

52wk Low:0.082

Shares:418.22M

Float Shares:347.84M

Volume Ratio:2.91

T/O Rate:1.67%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.024

EPS(LYR):-0.024

ROE:-42.41%

ROA:-20.06%

PB:9.14

PE(LYR):-17.33

Loading ...

Overview Company News Filings

Starpharma Holdings Insider Confidence Rewarded, Stock Hits AU$166m Market Cap

Simply Wall St.

3 ASX Penny Stocks With Market Caps Under A$200M

Simply Wall St.

Starpharma Holdings Limited's (ASX:SPL) market cap touched AU$155m last week, benefiting both retail investors who own 55% as well as institutions

Simply Wall St.

3 ASX Penny Stocks With Market Caps Under A$400M To Consider

Simply Wall St.

Thor Energy Partners with DISA Technologies to Remediate Abandoned Colorado Uranium Mines

Starpharma Holdings Secures $5.5 Million Upfront From Genentech for Oncology Drug Partnership

MT Newswires Live

Radiopharm Theranostics Ltd: Co Partners With Starpharma on Research and Option Agreement to Develop Novel Radiotherapy Asset

THOMSON REUTERS

Starpharma and Radiopharm Theranostics Partner to Develop Novel Radiotherapy Asset

BRIEF-Starpharma Holdings Signs Research And Option Agreement With Radiopharm Theranostics

Starpharma Holdings - Research and Option Agreement With Radiopharm Theranostics

THOMSON REUTERS

Starpharma Holdings - Agreement to Develop Novel Radiotherapy Asset

THOMSON REUTERS

Starpharma Holdings Ltd - to Receive $5.5 Mln Upfront, $564 Mln Milestones

THOMSON REUTERS

Starpharma Working With Roche Unit on Potential Cancer Therapies; Shares Hit Two-Year High

MT Newswires Live

Starpharma Holdings - Announces Collaboration and License Agreement With Genentech

THOMSON REUTERS

Starpharma Holdings Ltd - Agreement to Develop Innovative Dep Cancer Therapies

THOMSON REUTERS

Starpharma Holdings Ltd - to Receive $5.5 Mln Upfront, Eligible for Upto $564 Mln

THOMSON REUTERS

Starpharma FY Net Income AUD -10 Million

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SPL.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"SPL.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"SPL.AU\",,,,,undefined,":{"symbol":"SPL.AU","market":"AU","secType":"STK","nameCN":"STARPHARMA HOLDINGS LTD","latestPrice":0.415,"timestamp":1770700320000,"preClose":0.4,"halted":0,"volume":5819015,"delay":0,"changeRate":0.037499999999999895,"nameEN":"STARPHARMA HOLDINGS LTD","floatShares":347835291,"shares":418224781,"eps":-0.023946,"marketStatus":"Not Yet Opened","change":0.015,"latestTime":"02-10 16:12:00 AEDT","open":0.4,"high":0.415,"low":0.4,"amount":2334855,"amplitude":0.0375,"askPrice":0.42,"askSize":120625,"bidPrice":0.405,"bidSize":12469,"shortable":3,"etf":0,"ttmEps":-0.023946,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1770764400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.4,"openAndCloseTimeList":[[1770678000000,1770699600000]],"volumeRatio":2.914429,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"SPL.AU\",,,,,undefined,":{"symbol":"SPL.AU","floatShares":347835291,"roa":"-20.06%","roe":"-42.41%","lyrEps":-0.023946,"volumeRatio":2.914429,"shares":418224781,"dividePrice":0,"high":0.415,"amplitude":0.0375,"preClose":0.4,"low":0.4,"week52Low":0.082,"pbRate":"9.14","psRate":"29.67","week52High":0.445,"institutionHeld":0,"latestPrice":0.415,"committee":-0.812629,"eps":-0.023946,"divideRate":0,"volume":5819015,"delay":0,"ttmEps":-0.023946,"open":0.4,"prevYearClose":0.36,"prevWeekClose":0.37,"prevMonthClose":0.38,"prevQuarterClose":0.36,"fiveDayClose":0.42,"twentyDayClose":0.355,"sixtyDayClose":0.445},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SPL.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SPL.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SPL.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2607066750","title":"Starpharma Holdings Insider Confidence Rewarded, Stock Hits AU$166m Market Cap","url":"https://stock-news.laohu8.com/highlight/detail?id=2607066750","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607066750?lang=en_us&edition=fundamental","pubTime":"2026-01-30 04:28","pubTimestamp":1769718512,"startTime":"0","endTime":"0","summary":"Insiders who bought Starpharma Holdings Limited ( ASX:SPL ) stock in the last 12 months were richly rewarded last week...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-spl/starpharma-holdings-shares/news/starpharma-holdings-insider-confidence-rewarded-stock-hits-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-spl/starpharma-holdings-shares/news/starpharma-holdings-insider-confidence-rewarded-stock-hits-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7096","SPL.AU","BK7508","BK7501"],"gpt_icon":0},{"id":"2607543070","title":"3 ASX Penny Stocks With Market Caps Under A$200M","url":"https://stock-news.laohu8.com/highlight/detail?id=2607543070","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607543070?lang=en_us&edition=fundamental","pubTime":"2026-01-30 03:02","pubTimestamp":1769713359,"startTime":"0","endTime":"0","summary":"Australian shares are experiencing a period of relative stability, with investors cautiously observing market signals following the U.S. Federal Reserve's decision to hold rates steady and a recent unexpected inflation rise. In this context, penny stocks—often seen as smaller or newer companies—remain an intriguing investment area due to their potential for growth when supported by solid financial health. Despite being considered somewhat outdated, these stocks continue to offer opportunities...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-spl/starpharma-holdings-shares/news/3-asx-penny-stocks-with-market-caps-under-a200m-7","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-spl/starpharma-holdings-shares/news/3-asx-penny-stocks-with-market-caps-under-a200m-7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SPL.AU","SKS.AU","BK7506","BK7055","XAO.AU","BK7077","BK7096","BK7095","XJO.AU","AEF.AU","VRS.AU","XKO.AU","BK7508","BK7104","IGL.AU","LEX.AU","MSV.AU","BK7050","MTO.AU","BK7045","BK7062","SSM.AU","BK7128","BK7143","MXI.AU","AAL.AU","BK7023","BK7501","WAF.AU","DSK.AU"],"gpt_icon":0},{"id":"2593217404","title":"Starpharma Holdings Limited's (ASX:SPL) market cap touched AU$155m last week, benefiting both retail investors who own 55% as well as institutions","url":"https://stock-news.laohu8.com/highlight/detail?id=2593217404","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593217404?lang=en_us&edition=fundamental","pubTime":"2025-12-24 11:06","pubTimestamp":1766545606,"startTime":"0","endTime":"0","summary":"Key Insights The considerable ownership by retail investors in Starpharma Holdings indicates that they collectively...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-spl/starpharma-holdings-shares/news/starpharma-holdings-limiteds-asxspl-market-cap-touched-au155","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-spl/starpharma-holdings-shares/news/starpharma-holdings-limiteds-asxspl-market-cap-touched-au155","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7096","SPL.AU","BK7508","BK7501"],"gpt_icon":0},{"id":"2584918904","title":"3 ASX Penny Stocks With Market Caps Under A$400M To Consider","url":"https://stock-news.laohu8.com/highlight/detail?id=2584918904","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584918904?lang=en_us&edition=fundamental","pubTime":"2025-11-19 10:05","pubTimestamp":1763517914,"startTime":"0","endTime":"0","summary":"The Australian market is experiencing a cautious phase, with traders pausing to assess recent volatility and upcoming significant earnings reports. For investors willing to explore beyond well-known stocks, penny stocks—typically representing smaller or newer companies—can offer intriguing opportunities. Despite the term's outdated connotations, these stocks can provide substantial value when they possess strong financial foundations and potential for growth.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-spl/starpharma-holdings-shares/news/3-asx-penny-stocks-with-market-caps-under-a400m-to-consider-2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-spl/starpharma-holdings-shares/news/3-asx-penny-stocks-with-market-caps-under-a400m-to-consider-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["XKO.AU","BK7501","FWD.AU","CBE.AU","PPS.AU","BK7095","SKS.AU","BK7104","SSM.AU","BK7016","BK7503","BK7506","XAO.AU","BK7096","BK7508","BK7012","BK7055","AAL.AU","BK7023","BK7077","BVS.AU","BK7014","IGL.AU","BK7128","DSK.AU","BK7143","SPL.AU","GWA.AU","MTO.AU","XJO.AU","WAF.AU","BK7045"],"gpt_icon":0},{"id":"2577323299","title":"Thor Energy Partners with DISA Technologies to Remediate Abandoned Colorado Uranium Mines","url":"https://stock-news.laohu8.com/highlight/detail?id=2577323299","media":"Small Caps","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577323299?lang=en_us&edition=fundamental","pubTime":"2025-10-23 11:40","pubTimestamp":1761190811,"startTime":"0","endTime":"0","summary":"Thor Energy has finalised plans with DISA Technologies to investigate the use of unique technologies to treat selected waste dumps at abandoned mines in Colorado, with the aim of recovering saleable uranium and other critical mineral concentrates.DISA recently became the first company in the US to receive a final service providers license  from the country’s Nuclear Regulatory Commission , which allows it to remediate uranium mine waste through the use of its patented high-pressure slurry ablation  system.The HPSA technology uses a mechanical chemical-free process to remove radionuclides and metals from mine waste, creating two solid media outputs while cleaning up the dumps by removing an average 90% of the uranium and radium-226 content from the waste.Thor holds 25% ownership rights to uranium minerals via its US subsidiary Standard Minerals, with London-listed Metals One holding the remaining 75%.DISA will operate the Colorado projects and pay all associated costs of economic evalua","market":"us","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/10/Thor-Energy-ASX-THR-Partners-DISA-Technologies-Remediate-Colorado-Uranium-Mines.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/10/Thor-Energy-ASX-THR-Partners-DISA-Technologies-Remediate-Colorado-Uranium-Mines.jpg"],"rights":{"source":"smallcap_stock","url":"https://smallcaps.com.au/thor-energy-partners-disa-technologies-remediate-abandoned-colorado-uranium-mines/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/thor-energy-partners-disa-technologies-remediate-abandoned-colorado-uranium-mines/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["URA","SPL.AU","BK4585","XAO.AU","BK4606","BK7083","BK7095","BK7508","THR.AU","BK7501","BK4588","GHY.AU","XKO.AU","NRC","BK4196","XJO.AU","BK7096"],"gpt_icon":0},{"id":"2577398073","title":"Starpharma Holdings Secures $5.5 Million Upfront From Genentech for Oncology Drug Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2577398073","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577398073?lang=en_us&edition=fundamental","pubTime":"2025-10-22 12:23","pubTimestamp":1761107008,"startTime":"0","endTime":"0","summary":"Starpharma Holdings  secured a $5.5 million upfront payment from Genentech under a new licensing agreement to develop dendrimer-drug conjugates using its proprietary dendrimer-enhanced product  platform with Genentech's oncology medicines, according to a Wednesday Australian bourse filing.The DEP technology enhances solubility, efficacy, pharmacokinetics, and safety across various drug types, including small molecules, peptides, proteins, chemotherapeutics, radiotheranostics, and antibody-drug conjugates, per the filing.The company is also eligible to receive up to $564 million in development, commercial, and sales milestones, along with tiered royalties on worldwide sales, the filing added.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","SPL.AU","BK7096","BK7501"],"gpt_icon":0},{"id":"2571345626","title":"Radiopharm Theranostics Ltd: Co Partners With Starpharma on Research and Option Agreement to Develop Novel Radiotherapy Asset","url":"https://stock-news.laohu8.com/highlight/detail?id=2571345626","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571345626?lang=en_us&edition=fundamental","pubTime":"2025-09-30 18:12","pubTimestamp":1759227125,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nFWN3VG0RF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","BK7501","BK7096","RAD.AU","SPL.AU"],"gpt_icon":0},{"id":"2571954633","title":"Starpharma and Radiopharm Theranostics Partner to Develop Novel Radiotherapy Asset","url":"https://stock-news.laohu8.com/highlight/detail?id=2571954633","media":"Small Caps","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571954633?lang=en_us&edition=fundamental","pubTime":"2025-09-30 10:11","pubTimestamp":1759198273,"startTime":"0","endTime":"0","summary":"The partnership, which follows six months of preliminary research under Starpharma’s Star Navigator drug development program, will see Radiopharm pay Starpharma a $500,000 for an exclusive option to licence the new asset.Starpharma has spent the past 12 months optimising Star Navigator, while showcasing the unique capabilities of dendrimers at high-profile scientific conferences to generate industry interest and open new avenues for collaboration.“The Star Navigator initiative was launched this year to facilitate partnerships by allowing collaborators to access and evaluate the benefits of our technology within their own research and development programs,” Starpharma chief executive officer Cheryl Maley said.“Our engagement with Radiopharm speaks to the value of our technology and will demonstrate how our DEP platform can help shape the future oftargeted cancer therapies.”She added that the collaboration does not impact the progress of Starpharma’s internal development efforts such as ","market":"us","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/09/Starpharma-Radiopharm-Theranostics-ASX-RAD-SPL-Develop-Novel-Radiotherapy-Asset.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/09/Starpharma-Radiopharm-Theranostics-ASX-RAD-SPL-Develop-Novel-Radiotherapy-Asset.jpg"],"rights":{"source":"smallcap_stock","url":"https://smallcaps.com.au/starpharma-radiopharm-theranostics-partner-develop-novel-radiotherapy-asset/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/starpharma-radiopharm-theranostics-partner-develop-novel-radiotherapy-asset/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["SPL.AU","BK7508","BK7096","RAD.AU","BK7501","BK7067"],"gpt_icon":0},{"id":"2571239874","title":"BRIEF-Starpharma Holdings Signs Research And Option Agreement With Radiopharm Theranostics","url":"https://stock-news.laohu8.com/highlight/detail?id=2571239874","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571239874?lang=en_us&edition=fundamental","pubTime":"2025-09-30 09:28","pubTimestamp":1759195702,"startTime":"0","endTime":"0","summary":"BRIEF-Starpharma Holdings Signs Research And Option Agreement With Radiopharm TheranosticsSept 30 (Reuters) - Radiopharm Theranostics Ltd RAD.AX:RESEARCH AND OPTION AGREEMENT WITH RADIOPHARM THERANOST","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nFWN3VG0ML:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7096","RAD.AU","SPL.AU","BK7501","BK7067"],"gpt_icon":0},{"id":"2571648713","title":"Starpharma Holdings - Research and Option Agreement With Radiopharm Theranostics","url":"https://stock-news.laohu8.com/highlight/detail?id=2571648713","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571648713?lang=en_us&edition=fundamental","pubTime":"2025-09-30 07:46","pubTimestamp":1759189589,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nFWN3VG0ML:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7508","SPL.AU","BK7501","BK7096","BK7067"],"gpt_icon":0},{"id":"2571364874","title":"Starpharma Holdings - Agreement to Develop Novel Radiotherapy Asset","url":"https://stock-news.laohu8.com/highlight/detail?id=2571364874","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571364874?lang=en_us&edition=fundamental","pubTime":"2025-09-30 07:46","pubTimestamp":1759189589,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nFWN3VG0ML:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7096","SPL.AU","RAD.AU","BK7501","BK7067"],"gpt_icon":0},{"id":"2569789080","title":"Starpharma Holdings Ltd - to Receive $5.5 Mln Upfront, $564 Mln Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2569789080","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569789080?lang=en_us&edition=fundamental","pubTime":"2025-09-22 19:30","pubTimestamp":1758540600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250922:nTUA3M4D3N:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7096","SPL.AU","BK7508"],"gpt_icon":0},{"id":"2569279992","title":"Starpharma Working With Roche Unit on Potential Cancer Therapies; Shares Hit Two-Year High","url":"https://stock-news.laohu8.com/highlight/detail?id=2569279992","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569279992?lang=en_us&edition=fundamental","pubTime":"2025-09-22 08:51","pubTimestamp":1758502282,"startTime":"0","endTime":"0","summary":"Starpharma Holdings  signed a collaboration and license agreement with Genentech, a member of the healthcare group Roche, to develop potential cancer therapies using Starpharma's proprietary product drug delivery technology for an upfront payment of $5.5 million, according to a Monday Australian bourse filing.The company will be eligible to receive up to $564 million in development, regulatory, and commercial milestones, as well as tiered royalties on global net sales of products resulting from the collaboration, the filing said. It granted Genentech an exclusive worldwide license under its intellectual property to commercialize products resulting from the parties' collaboration.The firm will use its technology to generate dendrimer-drug conjugates that incorporate Genentech medicines for oncology targets. However, it will not be permitted to generate products directed to these oncology targets for itself or third parties.Starpharma's shares soared nearly 77% in early trading on Monday","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","BK7508","SPL.AU","BK7096"],"gpt_icon":0},{"id":"2569832275","title":"Starpharma Holdings - Announces Collaboration and License Agreement With Genentech","url":"https://stock-news.laohu8.com/highlight/detail?id=2569832275","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569832275?lang=en_us&edition=fundamental","pubTime":"2025-09-22 06:51","pubTimestamp":1758495064,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250921:nFWN3V70GZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPL.AU","BK7508","BK7096","BK7501"],"gpt_icon":0},{"id":"2569727583","title":"Starpharma Holdings Ltd - Agreement to Develop Innovative Dep Cancer Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2569727583","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569727583?lang=en_us&edition=fundamental","pubTime":"2025-09-22 06:51","pubTimestamp":1758495064,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250921:nFWN3V70GZ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPL.AU","BK7096","BK7501","BK7508"],"gpt_icon":0},{"id":"2569275830","title":"Starpharma Holdings Ltd - to Receive $5.5 Mln Upfront, Eligible for Upto $564 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2569275830","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569275830?lang=en_us&edition=fundamental","pubTime":"2025-09-22 06:51","pubTimestamp":1758495064,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250921:nFWN3V70GZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7508","SPL.AU","BK7096"],"gpt_icon":0},{"id":"2562744012","title":"Starpharma FY Net Income AUD -10 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2562744012","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562744012?lang=en_us&edition=fundamental","pubTime":"2025-08-26 08:48","pubTimestamp":1756169282,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250826:nPLXB7AB41:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","BK7508","SPL.AU","BK7501"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":17,"code":"91000000","status":"200"}]}}